Hospital
Jefferson County Hospital
Jefferson County Hospital was paid $3.87M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoJEFFERSON COUNTY HOSPITAL
FAIRFIELD, IA 52556
FAIRFIELD, IA 52556
33aNPI1376648329assigned 09/14/2006
33bProvider typeCritical Access Hospital
28Total paid$3.87M
24GClaims120,475
24DCodes billed95
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Iowa
Rank by total paid#5 of 79
Median peer was paid$801K
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,283 | $673K | |
| 2019 | 23,613 | $683K | |
| 2020 | 16,119 | $508K | |
| 2021 | 17,509 | $495K | |
| 2022 | 15,654 | $508K | |
| 2023 | 13,610 | $490K | |
| 2024incomplete | 7,687 | $519K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 9,590 | 7,914 | $545K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 11% | 13,622 | 12,273 | $434K |
| 80053 | Comprehensive metabolic panel | 9.2% | 11,026 | 9,306 | $356K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8.8% | 12,929 | 10,841 | $342K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.0% | 3,195 | 2,498 | $309K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.0% | 5,584 | 4,956 | $193K |
| 36415 | Collection of venous blood by venipuncture | 4.7% | 19,589 | 15,717 | $182K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 4.4% | 687 | 656 | $170K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 706 | 635 | $170K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 599 | 573 | $87K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 1,106 | 1,065 | $72K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 1,555 | 1,390 | $69K |
83 more codes
| 87070 | 1.7% | 1,521 | $64K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 3,168 | $62K |
| 81001 | 1.4% | 3,534 | $54K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 2,532 | $49K |
| G0378 | Hospital observation service, per hour | 1.2% | 434 | $45K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 1,507 | $44K |
| 86140 | 1.0% | 2,928 | $39K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,427 | $36K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 616 | $35K |
| 82150 | <1% | 2,297 | $34K | |
| 83690 | <1% | 2,307 | $34K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 300 | $33K |
| 99285 | Emergency room visit (most serious) | <1% | 274 | $31K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,043 | $31K |
| 80061 | Lipid panel | <1% | 894 | $27K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 583 | $24K |
| 84484 | <1% | 1,144 | $22K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 965 | $19K |
| 82607 | <1% | 692 | $19K | |
| 83735 | <1% | 1,115 | $16K | |
| 83880 | <1% | 722 | $12K | |
| 87040 | <1% | 410 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 499 | $12K |
| 80306 | <1% | 271 | $11K | |
| 62323 | <1% | 43 | $11K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 15 | $9K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 31 | $9K |
| 83605 | <1% | 659 | $9K | |
| 85610 | <1% | 889 | $9K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 702 | $9K |
| 84145 | <1% | 482 | $8K | |
| 82728 | <1% | 204 | $8K | |
| 80320 | <1% | 259 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 311 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 328 | $7K |
| 87631 | <1% | 79 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $5K |
| 85652 | <1% | 805 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 730 | $5K |
| 82746 | <1% | 117 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 126 | $5K |
| 84703 | <1% | 172 | $5K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 47 | $5K |
| 80329 | <1% | 60 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 67 | $4K |
| 83550 | <1% | 193 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 32 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 165 | $4K |
| 83540 | <1% | 193 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 132 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 42 | $2K |
| 82803 | <1% | 76 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 308 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 269 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 43 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 41 | $1K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 86 | $1K |
| 84550 | <1% | 43 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 183 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 185 | $1K |
| 87081 | <1% | 60 | $916.24 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 140 | $897.64 |
| 87480 | <1% | 38 | $719.98 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 43 | $685.93 |
| 87660 | <1% | 38 | $512.06 | |
| 87510 | <1% | 38 | $512.06 | |
| 84439 | <1% | 27 | $497.89 | |
| 85018 | <1% | 34 | $468.80 | |
| 87430 | <1% | 33 | $388.33 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16 | $340.58 |
| 80143 | <1% | 16 | $295.85 | |
| 80179 | <1% | 14 | $268.67 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $259.68 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $259.68 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 40 | $159.54 |
| 84480 | <1% | 13 | $107.64 | |
| 87641 | <1% | 17 | $64.41 | |
| 87640 | <1% | 17 | $64.41 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15 | $59.03 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 13 | $46.57 |
| 99217 | <1% | 18 | $37.09 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 15 | $0.00 |
| A9270 | Non-covered item or service | 0% | 302 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFEICKERT, BRENT (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Jefferson County Hospital | Fairfield, IA | $15.51M |
| Jefferson County Hospital | Fairfield, IA | $704K |
| Jefferson County Hospital | Fairfield, IA | $81K |
| Jefferson County Hospital | Fairfield, IA | $6K |
| Jefferson County Hospital | Fairfield, IA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.